Dysregulated BA signaling drives cholestasis, NAFLD, and IBD by disrupting FXR-mediated anti-inflammatory pathways and promoting NLRP3 inflammasome activation via TGR5 suppression. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.